Webber M M, Buffkin D C, Juillard G J, Schwabe A D, Verma R C, Bennet L R
J Nucl Med. 1980 Dec;21(12):1194-6.
The metabolism of L-(1-14C)ornithine monohydrochloride was monitored in patients with histologically proven cancer and in normal volunteers. Following i.v. injection of 8 microCi C-14 ornithine (160 nmoles), the decarboxylation of ornithine--yielding 14CO2--was monitored for a 2.5-hr period using the ionization chamber and vibrating-reed electrometer of Tolbert, as modified by Davidson and Schwabe. Twelve normal subjects exhaled 7.3-15.7% of the administered C-14 (mean 12.6% s.d. 3.11%). In ten patients tested before initiation of therapy, recovery ranged from 18.2-32.1% (mean 23.02%, s.d. 4.52%). A t-test indicates a confidence level of > 99.5% that a significant difference exists between the two means. Re-testing of two normal volunteers showed little or no change in ornithine metabolism over a 2-5-mo period. Results from testing three cancer patients before and after therapy correlate well with clinical evidence of the presence of tumor burden.
对经组织学证实患有癌症的患者和正常志愿者体内的L-(1-¹⁴C)盐酸鸟氨酸代谢情况进行了监测。静脉注射8微居里的¹⁴C鸟氨酸（160纳摩尔）后，使用经戴维森和施瓦贝改进的托尔伯特电离室和振簧静电计，在2.5小时内监测鸟氨酸脱羧生成¹⁴CO₂的情况。12名正常受试者呼出的¹⁴C占给药量的7.3%-15.7%（平均12.6%，标准差3.11%）。在10名治疗开始前接受测试的患者中，¹⁴C的回收率在18.2%-32.1%之间（平均23.02%，标准差4.52%）。t检验表明，两种平均值之间存在显著差异的置信水平>99.5%。对两名正常志愿者进行的再次测试显示，在2至5个月的时间里，鸟氨酸代谢几乎没有变化。对三名癌症患者治疗前后进行测试的结果与肿瘤负荷存在的临床证据密切相关。
